169 related articles for article (PubMed ID: 33086575)
21. Gene expression profiling in bladder cancer identifies potential therapeutic targets.
Hussain SA; Palmer DH; Syn WK; Sacco JJ; Greensmith RMD; Elmetwali T; Aachi V; Lloyd BH; Jithesh PV; Arrand J; Barton D; Ansari J; Sibson DR; James ND
Int J Oncol; 2017 Apr; 50(4):1147-1159. PubMed ID: 28259975
[TBL] [Abstract][Full Text] [Related]
22. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer.
Bielli P; Panzeri V; Lattanzio R; Mutascio S; Pieraccioli M; Volpe E; Pagliarulo V; Piantelli M; Giannantoni A; Di Stasi SM; Sette C
Clin Cancer Res; 2018 Nov; 24(21):5422-5432. PubMed ID: 30012566
[No Abstract] [Full Text] [Related]
23. Proteome-based classification of Nonmuscle Invasive Bladder Cancer.
Stroggilos R; Mokou M; Latosinska A; Makridakis M; Lygirou V; Mavrogeorgis E; Drekolias D; Frantzi M; Mullen W; Fragkoulis C; Stasinopoulos K; Papadopoulos G; Stathouros G; Lazaris AC; Makrythanasis P; Ntoumas K; Mischak H; Zoidakis J; Vlahou A
Int J Cancer; 2020 Jan; 146(1):281-294. PubMed ID: 31286493
[TBL] [Abstract][Full Text] [Related]
24. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
[No Abstract] [Full Text] [Related]
25. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
[TBL] [Abstract][Full Text] [Related]
26. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
27. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
Kim D; Choi Y; Ireland J; Foreman O; Tam RN; Patel R; Schleifman EB; Motlhabi M; French D; Wong CV; Peters E; Molinero L; Raja R; Amler LC; Hampton GM; Lackner MR; Kabbarah O
PLoS One; 2016; 11(11):e0165856. PubMed ID: 27846280
[TBL] [Abstract][Full Text] [Related]
28. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.
Jung M; Lee JH; Kim B; Park JH; Moon KC
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699951
[TBL] [Abstract][Full Text] [Related]
33. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
34. Fibulin-3 promotes muscle-invasive bladder cancer.
Han AL; Veeneman BA; El-Sawy L; Day KC; Day ML; Tomlins SA; Keller ET
Oncogene; 2017 Sep; 36(37):5243-5251. PubMed ID: 28504717
[TBL] [Abstract][Full Text] [Related]
35. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
[TBL] [Abstract][Full Text] [Related]
36. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
37. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
38. Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients.
Morsi MI; Youssef AI; Hassouna ME; El-Sedafi AS; Ghazal AA; Zaher ER
J Egypt Natl Canc Inst; 2006 Mar; 18(1):82-92. PubMed ID: 17237854
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
40. Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.
Wang T; Liu Z; Wang X; Bai P; Sun A; Shao Z; Luo R; Wu Z; Zhang K; Li W; Xiao W; Duan B; Wang Y; Chen B; Xing J
Cancer Biol Ther; 2020 Aug; 21(8):709-716. PubMed ID: 32449441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
